Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Australia led the way on prescription psychedelics. Now the field is at a crossroads

23 August 2026 · By · Wire by Fusion42

Published

23 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

Australia

◆ Source

Read at smh.com.au →

◆ Verified

Fusion42 · 23 August 2026 · Fusion42 review

Australia's 2023 rescheduling of psilocybin and MDMA to allow prescription by authorised psychiatrists has sparked a race to establish psychedelic clinics for mental health treatment, signaling a shift in therapeutic approaches as US regulatory approvals for similar drugs approach.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

Australia’s drug rescheduling opens a new mental health treatment market via psychedelic clinics, launching fresh commercial opportunities and regulatory challenges you can act on now.

◆ Coverage

1 source · 23 Aug 2026

◆ Related on Wire

◆ Topics

Healthpsychedelicsmental-healthregulationaustraliadrug-rescheduling